LGND Ligand Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LGND

Price (delayed)

$69.38

Market cap

$1.18B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.98

Enterprise value

$1.23B

Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenx Inc., the company went public in 1992.

Highlights
The debt has plunged by 73% YoY and by 23% from the previous quarter
Ligand Pharmaceuticals's quick ratio has surged by 78% QoQ but it has shrunk by 76% YoY
Ligand Pharmaceuticals's EPS has shrunk by 158% YoY and by 56% QoQ
Ligand Pharmaceuticals's net income has plunged by 158% YoY and by 57% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ligand.com
Peers: AMGN SPPI MRK PFE

Key stats

What are the main financial stats of LGND
Market
Shares outstanding
17.08M
Market cap
$1.18B
Enterprise value
$1.23B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.96
Price to sales (P/S)
5.96
EV/EBIT
126.97
EV/EBITDA
18.44
EV/Sales
6.26
Earnings
Revenue
$196.25M
EBIT
$9.67M
EBITDA
$66.56M
Free cash flow
$120.02M
Per share
EPS
-$1.98
Free cash flow per share
$7.12
Book value per share
$35.37
Revenue per share
$11.63
TBVPS
$18.04
Balance sheet
Total assets
$762.67M
Total liabilities
$165.18M
Debt
$87.75M
Equity
$597.49M
Working capital
$164.79M
Liquidity
Debt to equity
0.15
Current ratio
2.67
Quick ratio
2.45
Net debt/EBITDA
0.64
Margins
EBITDA margin
33.9%
Gross margin
73.1%
Net margin
-17%
Operating margin
1.5%
Efficiency
Return on assets
-3.3%
Return on equity
-4.4%
Return on invested capital
2.8%
Return on capital employed
1.5%
Return on sales
4.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LGND stock price

How has the Ligand Pharmaceuticals stock price performed over time
Intraday
0.9%
1 week
-3.85%
1 month
-7.76%
1 year
-39.82%
YTD
3.86%
QTD
3.86%

Financial performance

How have Ligand Pharmaceuticals's revenue and profit performed over time
Revenue
$196.25M
Gross profit
$143.42M
Operating income
$3.04M
Net income
-$33.36M
Gross margin
73.1%
Net margin
-17%
The net margin has plunged by 172% YoY and by 65% from the previous quarter
Ligand Pharmaceuticals's net income has plunged by 158% YoY and by 57% from the previous quarter
The company's operating income has shrunk by 97% YoY and by 89% QoQ
Ligand Pharmaceuticals's operating margin has shrunk by 97% YoY and by 89% QoQ

Growth

What is Ligand Pharmaceuticals's growth rate over time

Valuation

What is Ligand Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.96
P/S
5.96
EV/EBIT
126.97
EV/EBITDA
18.44
EV/Sales
6.26
Ligand Pharmaceuticals's EPS has shrunk by 158% YoY and by 56% QoQ
LGND's P/B is 41% lower than its 5-year quarterly average of 3.3 and 2% lower than its last 4 quarters average of 2.0
The equity has declined by 27% year-on-year and by 27% since the previous quarter
The price to sales (P/S) is 51% lower than the 5-year quarterly average of 12.2 and 16% lower than the last 4 quarters average of 7.1
The revenue has declined by 19% year-on-year and by 4.8% since the previous quarter

Efficiency

How efficient is Ligand Pharmaceuticals business performance
The ROA has shrunk by 173% YoY and by 74% QoQ
Ligand Pharmaceuticals's return on sales has surged by 166% QoQ but it has shrunk by 84% YoY
The company's return on equity has shrunk by 161% YoY and by 69% QoQ
Ligand Pharmaceuticals's ROIC has plunged by 68% YoY

Dividends

What is LGND's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LGND.

Financial health

How did Ligand Pharmaceuticals financials performed over time
Ligand Pharmaceuticals's quick ratio has surged by 78% QoQ but it has shrunk by 76% YoY
LGND's current ratio has dropped by 76% year-on-year but it has soared by 64% since the previous quarter
The debt is 85% less than the equity
The debt has plunged by 73% YoY and by 23% from the previous quarter
The debt to equity has plunged by 63% YoY but it has grown by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.